
Spero Therapeutics, Inc.: updates and filings
Price
$0.90
November 17, 2026Market cap $52M
What Ploutos Investor adds for Spero Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 12, 2026next Feb 12, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
August 2026
June 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 12, 2026Results of operationsForm8-K
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 10, 2026Officer or director changeForm8-K
- Oct 28, 2026Shares registered for employeesFormS-8
- Oct 27, 2026Officer or director changeForm8-K
- Sep 10, 2026FilingFormEFFECT
- Aug 28, 2026Material agreement entered, other material eventsForm8-K
- Aug 28, 2026Shelf registration for future offeringsFormS-3
- Aug 12, 2026Results of operationsForm8-K
- Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 14, 2026Material agreement entered, new material financial obligation, Regulation FD disclosure, other material eventsForm8-K
- Jun 25, 2026Officer or director change, amended articles or bylaws, shareholder voteForm8-K
- Jun 23, 2026Shares registered for employeesFormS-8
- Jun 22, 2026Regulation FD disclosure, other material eventsForm8-K
- May 13, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 13, 2026Results of operationsForm8-K
- Apr 27, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 27, 2026Additional annual meeting materialFormDEFA14A
- Apr 27, 2026Annual meeting proxy statementFormDEF 14A
- Apr 13, 2026Preliminary proxy statementFormPRE 14A
- Mar 26, 2026Results of operationsForm8-K
- Mar 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Jan 30, 2026Officer or director change, other material eventsForm8-K
- Dec 19, 2025Other material eventsForm8-K
- Nov 13, 2025Results of operations, Regulation FD disclosureForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 12, 2026 | 8-K | Results of operations | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 10, 2026 | 8-K | Officer or director change | Document |
| Oct 28, 2026 | S-8 | Shares registered for employees | Document |
| Oct 27, 2026 | 8-K | Officer or director change | Document |
| Sep 10, 2026 | EFFECT | Filing | Document |
| Aug 28, 2026 | 8-K | Material agreement entered, other material events | Document |
| Aug 28, 2026 | S-3 | Shelf registration for future offerings | Document |
| Aug 12, 2026 | 8-K | Results of operations | Document |
| Aug 12, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 14, 2026 | 8-K | Material agreement entered, new material financial obligation, Regulation FD disclosure, other material events | Document |
| Jun 25, 2026 | 8-K | Officer or director change, amended articles or bylaws, shareholder vote | Document |
| Jun 23, 2026 | S-8 | Shares registered for employees | Document |
| Jun 22, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| May 13, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 13, 2026 | 8-K | Results of operations | Document |
| Apr 27, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 27, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 27, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 13, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Mar 26, 2026 | 8-K | Results of operations | Document |
| Mar 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Jan 30, 2026 | 8-K | Officer or director change, other material events | Document |
| Dec 19, 2025 | 8-K | Other material events | Document |
| Nov 13, 2025 | 8-K | Results of operations, Regulation FD disclosure | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Mar 21, 2017.
The full analysis
What do Spero Therapeutics's filings show?
The filings are where every one of Spero Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.